Skip to main content

Multimedia

This episode of IOL Radio features Dr Jason Levy, lead investigator of the OPuS One trial, which studied the quality of life outcomes after RFA using Medtronic’s OsteoCool system for the palliative treatment of painful osseous metastases.
Earlier this year, the Busch Clinic added Profound Medical’s TULSA system to its treatment options. TULSA, also called “inside-out” ablation, uses a unique cooling system to provide thermal protection of important anatomy. 
Pavan Khanna, MD, discusses the evolution of Y-90 for the treatment of HCC and reviews the LEGACY and DOSISPHERE trials, which highlight how TheraSphere™ is progressing Y-90 therapy towards more advanced dosimetry techniques and personalization.
Osman Ahmed, MD, FCIRSE, discusses the recently published LEGACY Study, which confirmed Boston Scientific’s TheraSphere™ as a neoadjuvant or standalone therapy in treating HCC.
IOL Radio Podcast: Dr Nora Tabori and Dr Riad Salem discuss LEGACY, a robust multicenter study confirming Boston Scientific’s TheraSphere™ as a neoadjuvant or standalone therapy in treating HCC.
In this episode of IOL Radio, we spoke with Jason Levy, MD, lead investigator of the OPuS One trial, to learn more about the study results.

In this video, Dr Ripal Gandhi discusses his experience with the TriNav™ Infusion System, including challenges, benefits, effectiveness, and more. Watch this short video to learn more about this simple, trackable, and compatible technology used…

Dr DeNittis discusses NuView Life Science’s VPAC1, a peptide platform that detects the overexpression of specific receptors that appear only on the surface of malignant cells for early diagnosis and therapy of cancer.
Back to Top